Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Anaptysbio Inc (ANAB)

Anaptysbio Inc (ANAB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 770,867
  • Shares Outstanding, K 27,433
  • Annual Sales, $ 75,000 K
  • Annual Income, $ -19,930 K
  • 60-Month Beta 0.06
  • Price/Sales 9.89
  • Price/Cash Flow N/A
  • Price/Book 1.90
Trade ANAB with:

Options Overview Details

View History
  • Implied Volatility 77.00%
  • Historical Volatility 34.96%
  • IV Percentile 24%
  • IV Rank 12.28%
  • IV High 170.52% on 03/05/21
  • IV Low 63.91% on 05/21/21
  • Put/Call Vol Ratio 0.33
  • Today's Volume 4
  • Volume Avg (30-Day) 17
  • Put/Call OI Ratio 1.33
  • Today's Open Interest 205
  • Open Int (30-Day) 66

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.78
  • Number of Estimates 5
  • High Estimate -0.39
  • Low Estimate -1.08
  • Prior Year -0.87
  • Growth Rate Est. (year over year) +10.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.11 +16.51%
on 08/25/21
28.40 -1.09%
on 09/22/21
+2.49 (+9.73%)
since 08/23/21
3-Month
22.77 +23.36%
on 08/05/21
28.40 -1.09%
on 09/22/21
+3.16 (+12.68%)
since 06/23/21
52-Week
13.92 +101.80%
on 09/25/20
35.85 -21.66%
on 02/12/21
+13.28 (+89.67%)
since 09/23/20

Most Recent Stories

More News
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and...

ANAB : 28.09 (-0.04%)
Glaxo's (GSK) Jemperli Gets FDA Approval for New Indication

The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating patients with mismatch repair-deficient recurrent/advanced solid tumors. This is the second approved indication for the drug.

GSK : 39.34 (+0.15%)
VRTX : 185.09 (+0.44%)
RGEN : 324.21 (+3.55%)
ANAB : 28.09 (-0.04%)
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

-- Second FDA Approval of PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GSK

ANAB : 28.09 (-0.04%)
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 86.67% and 8.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ANAB : 28.09 (-0.04%)
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and...

ANAB : 28.09 (-0.04%)
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and...

ANAB : 28.09 (-0.04%)
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 7.04% and -1.45%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ANAB : 28.09 (-0.04%)
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and...

ANAB : 28.09 (-0.04%)
European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and...

TSRO : 74.96 (+0.03%)
ANAB : 28.09 (-0.04%)
Glaxo (GSK) Gets FDA Nod for Endometrial Cancer Drug Jemperli

The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating women with recurrent or advanced dMMR endometrial cancer.

GSK : 39.34 (+0.15%)
RGEN : 324.21 (+3.55%)
CTLT : 141.02 (+2.78%)
ANAB : 28.09 (-0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

See More

Key Turning Points

3rd Resistance Point 28.80
2nd Resistance Point 28.50
1st Resistance Point 28.30
Last Price 28.09
1st Support Level 27.79
2nd Support Level 27.49
3rd Support Level 27.29

See More

52-Week High 35.85
Last Price 28.09
Fibonacci 61.8% 27.48
Fibonacci 50% 24.89
Fibonacci 38.2% 22.30
52-Week Low 13.92

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar